HONEYPOT (A randomised controlled trial of exit site application of Medihoney Antibacterial Wound Gel for the preventation of catheter-associated infections in peritoneal dialysis patients) (2007–2010)

That in peritoneal dialysis patients, the daily exit site application of standardised antibacterial honey (in addition to daily cleansing) will more effectively prevent exit site infections, tunnel infections and peritonitis associated with peritoneal dialysis (PD) catheters than the current standard treatment of intranasal mupirocin prophlaxis for nasal staphylococcal carriers.
Grant type:
Gambro Pty Ltd
  • Academic Title-Professor
    Princess Alexandra Hospital Southside Clinical Unit
    Faculty of Medicine
Funded by:
Gambro Pty Ltd